Adagene Inc.

2.10+0.1000+5.00%Vol 121.39K1Y Perf -85.96%
Jun 27th, 2022 15:59 DELAYED
BID2.00 ASK2.25
Open2.08 Previous Close2.00
Pre-Market- After-Market-
 - -  - -%
Target Price
27.19 
Analyst Rating
Strong Buy 1.25
Potential %
1.19K 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★+     54.29
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
2.58 
Earnings Rating
Market Cap91.97M 
Earnings Date
-
Alpha-0.12 Standard Deviation0.14
Beta-0.64 

Today's Price Range

1.982.21

52W Range

1.6020.98

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
2.44%
1 Month
-25.00%
3 Months
-47.37%
6 Months
-72.69%
1 Year
-85.96%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ADAG2.100.10005.00
AAPL141.660.00000.00
GOOG2 332.45-38.3100-1.62
MSFT264.89-2.8100-1.05
XOM89.032.13002.45
WFC40.24-0.5200-1.28
JNJ182.12-0.1700-0.09
FB196.640.99000.51
GE66.71-0.2900-0.43
JPM116.38-0.9400-0.80
Earnings HistoryEstimateReportedSurprise %
----
----
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume121.39K
Shares Outstanding43.79K
Shares Float43.79M
Trades Count321
Dollar Volume251.60K
Avg. Volume66.52K
Avg. Weekly Volume58.91K
Avg. Monthly Volume89.99K
Avg. Quarterly Volume50.67K

Adagene Inc. (NASDAQ: ADAG) stock closed at 2.1 per share at the end of the most recent trading day (a 5% change compared to the prior day closing price) with a volume of 121.39K shares and market capitalization of 91.97M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 198 people. Adagene Inc. CEO is Peter Luo.

The one-year performance of Adagene Inc. stock is -85.96%, while year-to-date (YTD) performance is -73.98%. ADAG stock has a five-year performance of %. Its 52-week range is between 1.6 and 20.9799, which gives ADAG stock a 52-week price range ratio of 2.58%

Adagene Inc. currently has a PE ratio of -1.10, a price-to-book (PB) ratio of 0.57, a price-to-sale (PS) ratio of 9.04, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -54.64%, a ROC of -176.65% and a ROE of -199.62%. The company’s profit margin is -%, its EBITDA margin is -3 485.70%, and its revenue ttm is $10.18 Million , which makes it $0.23 revenue per share.

Of the last four earnings reports from Adagene Inc., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Adagene Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Adagene Inc. is Strong Buy (1.25), with a target price of $27.19, which is +1 194.76% compared to the current price. The earnings rating for Adagene Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Adagene Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Adagene Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 92.25, ATR14 : 0.23, CCI20 : -89.81, Chaikin Money Flow : -0.23, MACD : -0.31, Money Flow Index : 10.76, ROC : -26.47, RSI : 16.95, STOCH (14,3) : 31.50, STOCH RSI : 0.82, UO : 32.39, Williams %R : -68.50), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Adagene Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (50.00 %)
1 (50.00 %)
0 (0.00 %)
Moderate Buy
1 (50.00 %)
1 (50.00 %)
1 (100.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.25
Strong Buy
1.25
Strong Buy
1.50

Adagene Inc.

Adagene Inc is a clinical-stage immunotherapy company focused on the design and discovery of antibodies for the treatment of cancer.

CEO: Peter Luo

Telephone: +86 51287773632

Address: No. 218, Xinghu Street, Suzhou Industrial Park, Suzhou 25125, , CN

Number of employees: 198

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

76%24%

Bearish Bullish

61%39%

Bearish Bullish

61%39%

News

Stocktwits